Global Real-World Evidence Solutions Market Size
Study Period | 2019 - 2030 |
Market Size (2025) | USD 1.61 Billion |
Market Size (2030) | USD 2.52 Billion |
CAGR (2025 - 2030) | 9.40 % |
Fastest Growing Market | Asia Pacific |
Largest Market | North America |
Market Concentration | Medium |
Major Players*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Global Real-World Evidence Solutions Market Analysis
The Global Real-World Evidence Solutions Market size is estimated at USD 1.61 billion in 2025, and is expected to reach USD 2.52 billion by 2030, at a CAGR of 9.4% during the forecast period (2025-2030).
The real-world evidence solutions industry is undergoing significant transformation as healthcare organizations increasingly embrace digital technologies and data-driven decision-making. This shift is characterized by the integration of advanced analytics, artificial intelligence, and machine learning capabilities to derive meaningful insights from vast amounts of healthcare data. The industry has witnessed a notable trend toward the development of comprehensive end-to-end solutions that address the entire product lifecycle, from drug development to post-market surveillance. Healthcare providers and pharmaceutical companies are increasingly investing in sophisticated data infrastructure and analytics platforms to better understand patient outcomes and treatment effectiveness in real-world settings.
Strategic partnerships and collaborations have become a cornerstone of industry growth, with real-world evidence companies forming alliances to expand their capabilities and market reach. In July 2023, IQVIA and JDRF collaborated to enhance the understanding of Type 1 diabetes using real-world data to facilitate evidence generation. Similarly, in June 2023, Flatiron Health partnered with the National Institute for Health and Care Excellence (NICE) to develop real-time evidence research methodologies. These partnerships demonstrate the industry's commitment to leveraging collective expertise and resources to advance the field of real-world evidence.
The industry is experiencing rapid innovation in data analytics and real-world evidence insights, particularly in oncology and rare diseases. Companies are developing increasingly sophisticated real-world evidence platforms that can process and analyze complex healthcare data sets, including electronic health records, claims data, and patient-reported outcomes. The emergence of clinico-genomic databases with tumor sequencing information has enabled more targeted drug development and personalized medicine approaches. Pharmaceutical companies are leveraging these advanced capabilities to conduct more efficient clinical trials and make more informed decisions about drug development and market access.
Regulatory frameworks and standards for real-world evidence continue to evolve, with authorities increasingly recognizing its value in healthcare decision-making. The industry has seen a growing emphasis on standardization and quality assurance in real-world evidence data collection and analysis. Healthcare organizations are investing in robust data governance frameworks and compliance measures to ensure the reliability and validity of real-world evidence. This has led to increased adoption of standardized protocols and methodologies for data collection, analysis, and reporting, enhancing the credibility and utility of real-world evidence in healthcare decision-making.
Global Real-World Evidence Solutions Market Trends
Shift from Volume- to Value-Based Care
The healthcare industry is experiencing a fundamental transformation from the traditional fee-for-service model to a value-based care approach, creating significant opportunities for real-world evidence solutions. Historically, hospitals operated on a fee-for-service approach where the goal was to deliver the greatest number of services to the maximum number of people. However, in response to changing markets and shared risk models, healthcare systems are transitioning to prioritize quality outcomes and cost-effectiveness. This shift requires healthcare providers to deliver the highest quality care at the lowest possible cost while minimizing repeat visits and unnecessary procedures, making ongoing wellness and preventative treatment key priorities.
The transition to value-based care is driving increased collaboration between payers, providers, and life sciences companies as they work to integrate their capabilities and develop risk management strategies. Real-world data and evidence play a crucial role in improving regulatory and payment decision-making while providing generalizable knowledge to support clinician and patient decision-making. The shift also enables more team-based care models where all providers work at the top of their license, increasing efficiency while delivering better overall patient experiences. Several value-based healthcare programs have already been implemented, with clear indications from the Centers for Medicare and Medicaid that these will continue to expand, creating opportunities for real-world evidence solutions to demonstrate treatment value and outcomes.
Increasing Aging Population and Prevalence of Chronic Diseases
The growing burden of chronic diseases globally has created an unprecedented demand for advanced technologies like real-world evidence to enhance medical product development and treatment effectiveness. According to the World Ageing Population report, approximately 702.9 million people worldwide were aged 65 years and above in 2019, with this number projected to reach 1,548.9 million by 2050. This demographic shift is particularly significant as almost half of all chronic disease deaths are attributable to cardiovascular diseases, cancer, obesity, and diabetes, all of which show increasing prevalence trends. Cancer Research UK suggests that if recent trends in major cancer incidence and population growth continue, there will be 27.5 million new cancer cases worldwide annually by 2040, representing a 61.7% increase from 2018.
The correlation between aging populations and chronic disease prevalence has created a pressing need for more sophisticated approaches to drug development and treatment evaluation. According to the World Health Organization, cardiovascular diseases are the leading cause of death globally, responsible for an estimated 17.9 million deaths annually, with this number expected to increase to more than 23.6 million by 2030. This increasing disease burden, combined with more complex patient populations, has made real-world clinical data crucial for identifying sub-populations that require non-traditional approaches to solving clinical problems. The technology enables researchers to test medication appropriateness for specific patient groups, leading to more individualized care and improved outcomes. This is particularly valuable in oncology, where real-world insights help complement and enhance the arena of developing new medical products while supporting more personalized treatment approaches.
Segment Analysis: By Component
Clinical Settings Data Segment in Real-World Evidence Solutions Market
The Clinical Settings Data segment dominates the global real-world evidence solutions market, commanding approximately 32% of the market share in 2024. This segment's prominence is attributed to its crucial role in allowing new knowledge creation and guiding the development of best practices from increasing individual clinical experiences. Clinical settings data encompasses comprehensive information ranging from health determinants and status indicators to care delivery reports, stored throughout healthcare systems in various databases. The segment's leadership position is further strengthened by its extensive utilization in clinical registries, which help evaluate available treatments, procedures, and therapies, while enabling healthcare professionals to understand how patients with different characteristics respond to various treatments. Device manufacturers and pharmaceutical developers particularly value this segment as it helps them track and understand the effectiveness, safety, and value of medical devices, therapies, and drugs in the market.
Remaining Segments in Real-World Evidence Solutions Market
The market's remaining segments include Claims Data, Patient-powered Data, Pharmacy Data, and Other Components, each serving distinct roles in the real-world evidence ecosystem. Real-world datasets from Claims Data provide valuable insights from insurance records and patient-provider communications, offering critical information about billable transactions and healthcare delivery systems. Patient-powered Data, through research networks, enables patients and their communities to contribute to knowledge generation for specific medical conditions. Pharmacy Data plays a vital role in providing quality healthcare through detailed patient and transaction-based information, while also supporting immunization registries and prescription drug monitoring programs. The Other Components segment encompasses various supplementary services and solutions that support the overall real-world evidence infrastructure, including specialized analytical tools and consulting services.
Segment Analysis: By Therapeutic Area
Oncology Segment in Global Real-World Evidence Solutions Market
The oncology segment dominates the global real-world evidence solutions market, accounting for approximately 34% of the total market share in 2024. This significant market position is driven by the high number of clinical trials conducted for oncology and the increasing prevalence of cancer worldwide. According to the World Health Organization's latest statistics, cancer remains the second leading cause of death globally. The increasing demand for personalized medicine and more precise requirements for oncology treatment has further strengthened this segment's position. With the increasing use of digital health solutions and experimental cancer therapies, real-world data supports numerous aspects of medical research and routine clinical practice. Pragmatic trials, which are designed to evaluate the effectiveness of interventions in real-life situations, combine real-world evidence and information from randomized trials to support the effects of existing treatments in practice. This allows oncologists to get involved in helping more patients access novel treatments, particularly in the later stages of studies.
Cardiovascular Disease Segment in Global Real-World Evidence Solutions Market
The cardiovascular disease segment has emerged as a significant growth driver in the real-world evidence solutions market, with substantial expansion projected for the period 2024-2029. This growth is primarily attributed to the increasing global burden of cardiovascular diseases and the rising demand for effective treatment solutions. The segment's growth is further supported by the extensive use of real-time data registries, such as those in the American College of Cardiology National Cardiovascular Data Registry, which collect real-time patient data on specific cardiac conditions. These registries are continually updated with real-time data on patients and their conditions, therapy, and outcomes, providing comprehensive snapshots of actual care and outcomes associated with particular conditions. The real-world evidence generated by these registries and other data sources is increasingly being used by cardiologists alongside randomized clinical trial data to make informed treatment decisions.
Remaining Segments in Therapeutic Area
The other significant segments in the real-world evidence solutions market include immunology, neurology, and other therapeutic areas, each contributing uniquely to the market's dynamics. The immunology segment is driven by the increasing number of immunological and autoimmune disorders, while the neurology segment benefits from the growing focus on conditions such as Alzheimer's disease and Parkinson's disease. The other therapeutic areas segment encompasses fields such as ophthalmology and orthopedics, where real-world evidence plays a crucial role in understanding treatment outcomes and patient responses. These segments collectively demonstrate the broad application of real-world datasets across various medical fields, highlighting its importance in advancing healthcare solutions and improving patient outcomes across different therapeutic domains.
Segment Analysis: By End User
Pharmaceutical and Medical Device Companies Segment in Real-World Evidence Solutions Market
The pharmaceutical and medical device companies segment dominates the global real-world evidence solutions market, accounting for approximately 42% of the market share in 2024. This segment's prominence is driven by the increasing importance of real-world clinical data in product development and approvals, particularly in assessing real-world outcomes of drugs and devices in clinical settings. The segment has emerged as a crucial component for pharmaceutical and medical device companies in their post-market surveillance activities, helping them avoid recall costs and optimize product performance. The integration of advanced digital technologies and the launch of new products and services have further strengthened this segment's position. Many organizations are actively collaborating to expand the use of real-world evidence in chronic diseases and other therapeutic areas, demonstrating the segment's vital role in advancing healthcare solutions. The segment's growth is also supported by the increasing adoption of real-world analysis to enhance accuracy in decision-making processes and the rising demand for data-driven insights in drug development and commercialization strategies.
Remaining Segments in End User Market
The healthcare payers segment plays a vital role in the market by utilizing real-world evidence to improve healthcare affordability and integrate claims with EMR data for generating insights into provider effectiveness. The healthcare providers segment leverages real-world evidence to enhance clinical decision-making and patient care through evidence-based methodologies and systems. These segments benefit from the increasing digitalization of healthcare services and the shift toward patient-centered virtual care. The other end users segment, which includes regulators and academics, contributes to the market by utilizing real-world evidence for regulatory decision-making and academic research purposes. These segments collectively demonstrate the diverse applications and growing importance of real-world evidence across the healthcare ecosystem, from clinical practice to policy-making and research.
Global Real-World Evidence Solutions Market Geography Segment Analysis
Real-World Evidence Solutions Market in North America
North America represents the most mature and largest market for the global real-world evidence solutions market. The region benefits from advanced healthcare infrastructure, widespread adoption of electronic health records, and a strong presence of major pharmaceutical companies. The United States, Canada, and Mexico comprise this market, with each country showing distinct characteristics in terms of RWE adoption. The presence of key real-world evidence companies and increasing research and development of new drugs and medical devices in the region continues to boost the usage of advanced clinical data solutions.
Real-World Evidence Solutions Market in United States
The United States dominates the North American market, accounting for approximately 48% of the global real-world evidence solutions market share in 2024. The country's leadership position is supported by continuous support from regulatory authorities in the adoption of advanced digital solutions. The 21st Century Cures Act has established public-private partnerships in data collection to gain insights on diseases, which help in targeted drug development and clinical trial design. The presence of key market players, coupled with the increasing research and development of new drugs and medical devices, continues to boost the usage of advanced clinical data solutions such as real-world evidence solutions in the country.
Real-World Evidence Solutions Market Growth Trajectory in United States
The United States is also experiencing the fastest growth in the North American region, with a projected CAGR of approximately 16% from 2024 to 2029. This growth is driven by the increasing adoption of real-world evidence studies and the strong focus on personalized medicine. The country's robust healthcare infrastructure and the presence of major pharmaceutical companies contribute to this growth. Additionally, the shift towards value-based healthcare and the increasing emphasis on patient-centered care are creating new opportunities for real-world evidence solutions in the United States.
Real-World Evidence Solutions Market in Europe
Europe represents a significant market for real-world evidence solutions, characterized by diverse healthcare systems and regulatory frameworks across different countries. The region encompasses major markets including Germany, France, the United Kingdom, Italy, and Spain, each with its unique approach to RWE adoption. The European market benefits from strong healthcare infrastructure, increasing digitalization of healthcare services, and a supportive regulatory environment for real-world evidence implementation.
Real-World Evidence Solutions Market in Germany
Germany leads the European market, commanding approximately 18% of the regional market share in 2024. As one of the largest pharmaceutical markets in the world and the largest in Europe, Germany has witnessed significant changes in its corporate management culture across all industries. The country's leadership in RWE adoption is supported by recent legislative reforms and an increasing focus on digital health initiatives. The German healthcare system's emphasis on evidence-based medicine and value-based care has created a favorable environment for RWE solutions.
Real-World Evidence Solutions Market Growth Trajectory in Germany
Germany is experiencing the highest growth rate in the European region, with an expected CAGR of approximately 15% from 2024 to 2029. This growth is driven by the country's strong focus on healthcare innovation and digital transformation. The German Ministry of Health's initiatives to improve drug safety and enhance the use of patient-reported real-world evidence collection, particularly in rare diseases, are contributing to this growth. The country's robust pharmaceutical research and development infrastructure continues to support the expansion of RWE applications.
Real-World Evidence Solutions Market in Asia-Pacific
The Asia-Pacific region represents a dynamic and rapidly evolving market for real-world evidence solutions, encompassing diverse healthcare systems and regulatory environments. Key markets include China, Japan, India, South Korea, and Australia, each at different stages of RWE adoption and implementation. The region is characterized by increasing healthcare expenditure, growing digital health initiatives, and a rising emphasis on evidence-based medicine.
Real-World Evidence Solutions Market in China
China leads the Asia-Pacific market in terms of market size, demonstrating strong growth potential and increasing adoption of RWE solutions. The country has made significant strides in establishing regulatory frameworks for real-world evidence, with the National Medical Products Administration (NMPA) actively promoting the use of RWE in drug development and registration. China's large patient population and growing healthcare infrastructure make it an attractive market for RWE solutions.
Real-World Evidence Solutions Market Growth Trajectory in China
China is also experiencing the fastest growth rate in the Asia-Pacific region. The country's commitment to healthcare modernization and digital transformation is driving this growth. The Chinese government's initiatives to build regulatory and technical level systems, while improving active drug warning systems, are contributing to the expansion of RWE applications. The increasing focus on personalized medicine and the growing pharmaceutical research sector further support this growth trajectory.
Real-World Evidence Solutions Market in Middle East & Africa
The Middle East & Africa region represents an emerging market for real-world evidence solutions, with varying levels of healthcare infrastructure development across different countries. The region encompasses the GCC countries and South Africa as key markets. The GCC leads the regional market both in terms of market size and growth rate, benefiting from robust healthcare infrastructure and the highest per capita drug expenditure in the region. South Africa follows with moderate growth, while other countries in the region are gradually developing their RWE capabilities.
Real-World Evidence Solutions Market in South America
The South American market for real-world evidence solutions is characterized by growing adoption of digital healthcare solutions and an increasing focus on evidence-based medicine. The region includes Brazil and Argentina as key markets, with Brazil leading both in terms of market size and growth rate. The region's healthcare sector is experiencing significant transformation, with increasing investments in healthcare infrastructure and a growing emphasis on real-world evidence for clinical decision-making. While regulatory frameworks are still evolving, there is a growing recognition of the importance of RWE in improving healthcare outcomes.
Global Real-World Evidence Solutions Industry Overview
Top Companies in Real-World Evidence Solutions Market
The real-world evidence solutions market features prominent players like IQVIA, Oracle Corporation, IBM, Parexel International, PPD Inc., and other technology and healthcare specialists. These real-world evidence companies are driving innovation through advanced analytics platforms, AI-powered solutions, and cloud-based technologies to process vast amounts of healthcare data. Strategic partnerships and collaborations, particularly with healthcare providers and research institutions, have become increasingly common to expand data access and enhance solution capabilities. Companies are investing heavily in R&D to develop comprehensive end-to-end RWE platforms that can support the entire product lifecycle from drug development to post-market surveillance. Geographic expansion, especially into emerging markets, remains a key focus area with companies establishing regional centers of excellence and data partnerships to strengthen their global presence.
Market Dominated by Technology-Healthcare Hybrid Leaders
The real-world evidence solutions market exhibits a unique structure where technology giants and specialized healthcare analytics providers compete and collaborate simultaneously. Large conglomerates like IBM and Oracle leverage their extensive technological infrastructure and global presence to offer comprehensive RWE platforms, while specialized firms like IQVIA and Parexel bring deep domain expertise in healthcare analytics and clinical research. The market is experiencing ongoing consolidation through strategic acquisitions, particularly targeting companies with specialized capabilities in areas such as natural language processing, AI-driven analytics, and disease-specific data assets.
The competitive landscape is characterized by high barriers to entry due to the need for sophisticated technology infrastructure, extensive healthcare domain knowledge, and established relationships with data providers. Market leaders are increasingly pursuing vertical integration strategies, acquiring or partnering with healthcare providers, research organizations, and real-world data vendors to create comprehensive RWE ecosystems. The industry has witnessed numerous strategic partnerships and collaborations aimed at combining complementary capabilities, expanding geographic reach, and enhancing service offerings across different therapeutic areas.
Innovation and Integration Drive Market Success
Success in the real-world evidence solutions market increasingly depends on the ability to provide integrated, end-to-end solutions that address the entire healthcare value chain. Companies must focus on developing robust data governance frameworks, ensuring data quality and compliance with evolving regulatory requirements, while simultaneously investing in advanced analytics capabilities. The ability to demonstrate tangible value through improved patient outcomes, reduced healthcare costs, and accelerated drug development timelines has become crucial for market players to maintain their competitive position.
Market participants need to address several critical factors to maintain or gain market share, including the development of specialized therapeutic area expertise, enhancement of data integration capabilities, and establishment of strong relationships with healthcare stakeholders. The increasing focus on value-based healthcare and personalized medicine creates opportunities for companies that can effectively combine real-world data with advanced analytics to generate actionable insights. Regulatory developments, particularly around data privacy and the acceptance of real-world evidence in clinical decision-making, continue to shape competitive strategies and market dynamics.
Global Real-World Evidence Solutions Market Leaders
-
IQVIA Inc
-
IBM
-
Lindus Health Limited
-
ICON plc
-
Oracle
*Disclaimer: Major Players sorted in no particular order
Global Real-World Evidence Solutions Market News
- July 2024: HealthVerity, a real-world data (RWD) technologies provider, and Castor, a provider of decentralized and hybrid clinical trial solutions, entered a strategic partnership to streamline the synchronization of clinical trial and real-world data throughout the clinical research stages.
- May 2024: Omega Healthcare released the details of poster sessions co-presented with partners Memorial Sloan Kettering Cancer Center (MSK) and Dana-Farber Cancer Institute (DFCI) at the AACR Annual Meeting 2024. The sessions described how MSK and DFCI partnered with Omega Healthcare to deliver high-quality, real-world data (RWD) for 6,000+ cancer patients as part of the AACR Project GENIE Biopharma Collaborative (BPC).
Global Real-World Evidence Solutions Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definitions
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Government Initiatives Boosting Adoption of Real World Evidence Solutions Coupled With Surge in R&D Investments
4.2.2 Growing Adoption of Technological Innovations in Real World Evidence Solutions
4.3 Market Restraints
4.3.1 Lack of Presence of Standardized Regulations Coupled Shortage of Skilled Professionals
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
5.1 By Component
5.1.1 Services
5.1.2 Data Sets
5.1.2.1 Clinical Settings Data
5.1.2.2 Claims Data
5.1.2.3 Pharmacy Data
5.1.2.4 Patient Powered Data
5.1.2.5 Other Components (Disease Registries, Electronic Health Records, and Other Components)
5.2 By Therapeutic Area
5.2.1 Oncology
5.2.2 Cardiology
5.2.3 Diabetes
5.2.4 Neurology
5.2.5 Psychiatry
5.2.6 Other Therapeutic Areas (Orthopedics, Respiratory, and Other Therapeutic Areas)
5.3 By Application
5.3.1 Drug Development and Approvals
5.3.2 Medical Device Development and Approvals
5.3.3 Pharmacovigilance Studies
5.3.4 Regulatory Decision-making and Reimbursement/Coverage
5.4 By End User
5.4.1 Pharmaceutical and Medical Device Companies
5.4.2 Clinica Research Organization
5.4.3 Healthcare Providers
5.4.4 Other End Users
5.5 Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 United Kingdom
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 Australia
5.5.3.5 South Korea
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle East and Africa
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle East and Africa
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 IQVIA Inc.
6.1.2 IBM
6.1.3 Lindus Health Limited
6.1.4 ICON PLC
6.1.5 Oracle
6.1.6 Syneos Health
6.1.7 Verto Healthcare
6.1.8 Medspace
6.1.9 Thermo Fisher Scientific Inc. (CorEvitas)
6.1.10 TriNetX LLC
6.1.11 Optum Inc.
6.1.12 PerkinElmer Inc.
6.1.13 Flatiron Health
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Global Real-World Evidence Solutions Industry Segmentation
As per the scope of the report, real-world evidence (RWE) is the clinical evidence about the usage and potential benefits or risks of a medical product derived from analysis of real-world data (RWD).
The real-world evidence solutions market is segmented into components, therapeutic areas, applications, end users, and geography. By component, the market is segmented into services and data sets (clinical setting data, claims data, pharmacy data, patient-powered data, and other components (disease registries and electronic health records). By therapeutic area, the market is segmented into oncology, cardiology, diabetes, neurology, psychiatry, and other therapeutic areas (orthopedics and respiratory). By application, the market is segmented into drug development and approvals, medical device development and approvals, pharmacovigilance studies, and regulatory decision-making and reimbursement/coverage. By end user, the market is segmented into pharmaceutical and medical device companies, clinical research organizations, and healthcare providers. By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America.
The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (USD) for the above segments.
By Component | |||||||
Services | |||||||
|
By Therapeutic Area | |
Oncology | |
Cardiology | |
Diabetes | |
Neurology | |
Psychiatry | |
Other Therapeutic Areas (Orthopedics, Respiratory, and Other Therapeutic Areas) |
By Application | |
Drug Development and Approvals | |
Medical Device Development and Approvals | |
Pharmacovigilance Studies | |
Regulatory Decision-making and Reimbursement/Coverage |
By End User | |
Pharmaceutical and Medical Device Companies | |
Clinica Research Organization | |
Healthcare Providers | |
Other End Users |
Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Global Real-World Evidence Solutions Market Research FAQs
How big is the Global Real-World Evidence Solutions Market?
The Global Real-World Evidence Solutions Market size is expected to reach USD 1.61 billion in 2025 and grow at a CAGR of 9.40% to reach USD 2.52 billion by 2030.
What is the current Global Real-World Evidence Solutions Market size?
In 2025, the Global Real-World Evidence Solutions Market size is expected to reach USD 1.61 billion.
Who are the key players in Global Real-World Evidence Solutions Market?
IQVIA Inc, IBM, Lindus Health Limited, ICON plc and Oracle are the major companies operating in the Global Real-World Evidence Solutions Market.
Which is the fastest growing region in Global Real-World Evidence Solutions Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Global Real-World Evidence Solutions Market?
In 2025, the North America accounts for the largest market share in Global Real-World Evidence Solutions Market.
What years does this Global Real-World Evidence Solutions Market cover, and what was the market size in 2024?
In 2024, the Global Real-World Evidence Solutions Market size was estimated at USD 1.46 billion. The report covers the Global Real-World Evidence Solutions Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Global Real-World Evidence Solutions Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Global Real-World Evidence Solutions Market Research
Mordor Intelligence provides a comprehensive analysis of the real-world evidence solutions market. We leverage our extensive expertise in pharma real world data and healthcare analytics. Our research thoroughly examines real world evidence companies and their solutions. It incorporates real world clinical data from diverse sources. The report, available as an easy-to-download PDF, offers detailed insights into real world data vendors and their offerings. It also analyzes emerging trends in real-world datasets and evidence-based decision-making platforms.
The report benefits stakeholders by offering detailed real world evidence market size projections and analysis of real world data companies across global markets. Our extensive coverage includes an evaluation of real world evidence services and platforms. This enables healthcare organizations to make informed decisions. The research encompasses real world evidence trends and real-world insights, supported by robust RWE analytics and real world solutions implementation strategies. Stakeholders gain access to comprehensive real world data market size analysis and detailed assessments of real world evidence vendors. This ensures strategic alignment with market developments.